SUNRAY-01

Lung Cancer

A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pemetrexed and Platinum for the First-line treatment of Participants with KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer.

Key Team Members

Principal Investigator

Scott Graupner, DO

Research Coordinator

Selena Lollar

Accepting Patients

Enrollment Started: July 31, 2025

Check if You’re Eligible

(803) 935-8300

Research@lexhealth.org

About the Trial

This study is being done to see how safe an investigational drug is and how well it will work to help people with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (type of lung cancer caused by a gene alteration). Investigational means that the drug being tested has not been approved for routine clinical use or for the use described in this study by the United States Food and Drug Administration (FDA). The FDA is allowing the use of this drug for research.